Skip to main content
Clinical Trials/NCT02099968
NCT02099968
Completed
Not Applicable

Intensivierte Ernährungs- Und Lebensstilmodifikation Bei Patienten Mit Bluthochdruck Und Kardiometabolischer Risikokonstellation. Eine Zweizentrische Randomisiert-kontrollierte Interventionsstudie über 6 Monate

Universität Duisburg-Essen2 sites in 1 country145 target enrollmentApril 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypertension
Sponsor
Universität Duisburg-Essen
Enrollment
145
Locations
2
Primary Endpoint
Systolic blood pressure
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Different forms of diet, e.g. Mediterranean diet, DASH diet, or fasting, have demonstrated efficacy in reducing elevated blood pressure. Moreover, Mediterranean diet, and fasting seem to be effective in improving insulin sensitivity in type 2 diabetes. Further, studies on meditation or mindfulness-based interventions have shown positive effects in patients with hypertension and/or type 2 diabetes. Comprehensive Lifestyle Modification, this is a combination of diet, exercise, and stress management, have improved coronary atherosclerosis. However, no studies have yet investigated the effects of Comprehensive Lifestyle Modification in patients with metabolic syndrome and/or in combination with fasting therapy.

This study is supported by a grant from the Corona-Foundation, Germany.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
December 2015
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gustav Dobos

Head of Department

Universität Duisburg-Essen

Eligibility Criteria

Inclusion Criteria

  • Hypertension or antihypertensive medication or subclinical atherosclerosis
  • Metabolic syndrome
  • Basic mobility

Exclusion Criteria

  • Diabetes type 1
  • Insulin bolus therapy
  • Coronary artery disease
  • Myocardial infarct, pulmonary embolism, or stroke within the past 3 months
  • Heart failure
  • Peripheral vascular disease
  • Chronic kidney disease
  • Eating disorder
  • Other severe internal disease

Outcomes

Primary Outcomes

Systolic blood pressure

Time Frame: 3 months

24-hour ambulatory blood pressure

HOMA Index

Time Frame: 3 months

Homeostatic Model Assessment

Secondary Outcomes

  • CRP(1 week, 3 months, 6 months, 12 months)
  • Framingham-Score(1 week, 3 months, 6 months, 12 months)
  • JBS3-Score(1 week, 3 months, 6 months, 12 months)
  • SCORE(1 week, 3 months, 6 months, 12 months)
  • Blood creatinine level(1 week, 3 months, 6 months, 12 months)
  • HDL cholesterol(1 week, 3 months, 6 months, 12 months)
  • POMS(1 week, 3 months, 6 months, 12 months)
  • SWE(1 week, 3 months, 6 months, 12 months)
  • SCS(1 week, 3 months, 6 months, 12 months)
  • HADS(1 week, 3 months, 6 months, 12 months)
  • Waist circumference(1 week, 3 months, 6 months, 12 months)
  • Blood glucose level(1 week, 3 months, 6 months, 12 months)
  • PROCAM(1 week, 3 months, 6 months, 12 months)
  • Blood insulin level(1 week, 3 months, 6 months, 12 months)
  • HbA1C(3 months, 6 months, 12 months)
  • Pulse wave velocity(3 months, 6 months, 12 months)
  • SF-36(3 months, 6 months, 12 months)
  • MAAS(3 months, 6 months, 12 months)
  • Bioelectrical impedance analysis(1 week, 3 months, 6 months, 12 months)
  • Immunophenotyping(1 week, 3 months, 6 months)
  • Gene expression profiling(1 week, 3 months)
  • Blood pressure(1 week, 3 months, 6 months, 12 months)
  • Weight(1 week, 3 months, 6 months, 12 months)
  • Total cholesterol(1 week, 3 months, 6 months, 12 months)
  • LDL cholesterol(1 week, 3 months, 6 months, 12 months)
  • Medication use(1 week, 3 months, 6 months, 12 months)
  • CPSS(3 months, 6 months, 12 months)
  • Lifestyle questionnaire(3 months, 6 months, 12 months)
  • Hair steroid analysis(6 months, 12 months)
  • Waist/hip ratio(1 week, 3 months, 6 months, 12 months)
  • Insulin-like growth factor (IGF-1)(1 week, 3 months, 6 months, 12 months)
  • Intestinal microbiota(1 week, 3 months, 6 months)
  • Interleukin- 6(1 week, 3 months, 6 months, 12 months)
  • Uric acid(1 week, 3 months, 6 months, 12 months)
  • Metabolomics(1 week, 3 months)
  • Adverse events(1 week, 3 months, 6 months, 12 months)

Study Sites (2)

Loading locations...

Similar Trials